1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
New Jersey Resources reported fiscal 2026 second-quarter net income of $218.9 million, or $2.17 per share, up from $204.3 million, or $2.04 per share, a year earlier. The company raised its fiscal 2026 net financial earnings per share guidance by $0.20 to $3.48-$3.63, citing continued strong performance at Energy Services, which is the second increase this year.
Q2 net income was $218.9 million, or $2.17 per share, versus $204.3 million, or $2.04 per share, a year earlier.
Q2 net financial earnings (non-GAAP) were $221.5 million, or $2.20 per share, versus $178.3 million, or $1.78 per share.
Fiscal 2026 NFEPS guidance rose to $3.48-$3.63 from $3.28-$3.43, following a $0.25 increase announced in February 2026.
Energy Services Q2 NFE was $72.3 million versus $35.3 million; management will webcast results on May 5, 2026, at 10 a.m. ET.
Cryoport reported first-quarter 2026 revenue of $47.8 million, up 16% from a year earlier, and raised its full-year 2026 revenue guidance to $192 million to $196 million. Net loss narrowed to $10.5 million from $12.0 million, but the loss from continuing operations widened to $9.4 million from $6.7 million.
Q1 2026 total revenue was $47.8 million, up 16% year-over-year from $41.0 million.
Commercial cell and gene therapy revenue rose 26% to $9.1 million.
Net loss per share attributable to common stockholders was $0.25, compared with $0.28 in Q1 2025.
Cash, cash equivalents and short-term investments totaled $403.6 million as of March 31, 2026.
GeneDx reported first-quarter 2026 revenue of $102.3 million, up 17% year over year, but lowered its full-year 2026 revenue guidance to $475 million to $490 million from $540 million to $555 million. The company also reported a GAAP net loss of $63.3 million, including a $31.3 million impairment loss, which matters to shareholders because the revenue outlook has been reset and the quarter swung from a year-earlier adjusted profit to an adjusted loss.
Q1 2026 revenue was $102.3 million, up 17% from $87.1 million a year earlier; exome and genome test revenue rose 27% to $90.6 million.
Full-year 2026 revenue guidance was updated to $475 million to $490 million, down from the previous $540 million to $555 million.
GAAP net loss was $63.3 million, or $2.16 per share, including a $31.3 million impairment loss; adjusted net loss was $8.2 million versus adjusted net income of $9.2 million in Q1 2025.
Cash, cash equivalents, marketable securities and restricted cash totaled $171.7 million as of March 31, 2026.
V2X reported first-quarter 2026 revenue of $1.25 billion, up 23% from a year earlier, and net income of $18.9 million, or $0.60 per diluted share, compared with $8.1 million, or $0.25 per diluted share, a year earlier. The company raised its full-year 2026 guidance ranges for revenue, adjusted EBITDA, adjusted diluted EPS and adjusted operating cash flow, which matters to shareholders because it changes the company's stated expectations for the year.
First-quarter revenue of $1.25 billion, up 23% year over year; adjusted diluted EPS of $1.53, up 55%
Updated 2026 revenue guidance of $4,825 million to $4,975 million, up from $4,675 million to $4,825 million
Updated 2026 adjusted diluted EPS guidance of $5.75 to $6.15, up from $5.50 to $5.90
Net debt of $895.4 million at the end of the first quarter; net cash used by operating activities was $129.9 million
National Health Investors reported first quarter 2026 results, with diluted earnings per share up 10.8% to $0.82 and NAREIT FFO per diluted share up 7.9% to $1.23. The REIT also lowered its full-year 2026 NAREIT and Normalized FFO per diluted share guidance from $4.94-$4.99 to $4.74-$4.79, and the release says the updated range reflects assumptions including the timing of certain transactions.
Diluted EPS was $0.82 for the quarter ended March 31, 2026, versus $0.74 a year earlier, including $2.6 million of gains on property dispositions.
NAREIT FFO per diluted share was $1.23, versus $1.14 a year earlier; Normalized FAD rose 11.6% to $62.5 million.
2026 NAREIT FFO and Normalized FFO per diluted share guidance was cut to $4.74-$4.79 from $4.94-$4.99.
The pending sale of the NHC leased portfolio for $560.0 million in net cash consideration is expected to close on July 1, 2026.
Sterling Infrastructure reported first quarter 2026 revenue of $825.7 million, up 92%, and net income of $96.0 million, or $3.09 per diluted share, up 141%. The company raised its full year 2026 guidance, now calling for revenue of $3.70 billion to $3.80 billion and diluted EPS of $16.50 to $17.15, with the CEC acquisition a major contributor to growth.
Q1 2026 revenue of $825.7 million, up 92%; CEC contributed $156.1 million
Net income of $96.0 million, or $3.09 per diluted share; adjusted diluted EPS of $3.59, up 120%
Full year 2026 guidance: revenue of $3.70 billion to $3.80 billion; adjusted diluted EPS of $18.40 to $19.05
Building Solutions adjusted operating income fell 42%, and management expects challenging conditions through 2026
Inspire Medical Systems reported first-quarter 2026 revenue of $204.6 million, up 1.6% from a year earlier, but posted a net loss of $11.3 million, or $(0.39) per diluted share, compared with earnings of $0.10 per diluted share a year earlier. The company lowered its full-year 2026 revenue outlook to $825 million-$875 million, a decline of 4% to 10% from 2025, and said it expects coding and reimbursement uncertainty for Inspire V to persist through the rest of 2026.
Q1 2026 revenue rose 1.6% to $204.6 million; GAAP diluted EPS was $(0.39) versus $0.10 a year earlier.
Adjusted diluted EPS was $0.10; the company reported a $11.3 million net loss, which includes a $13.1 million tax impact of stock-based compensation.
2026 revenue guidance revised to $825 million-$875 million; diluted EPS guidance of $0.07-$0.62 and adjusted diluted EPS guidance of $0.75-$1.25.
Management expects to return to revenue growth in 2027; the earnings call is set for 5:00 p.m. Eastern Time on May 4, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.